all report title image
  • Published On : Sep 2022
  • Code : CMI5255
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :

Skin fibrosis disease is a critical clinical condition resulting in serious disability and badly affecting morbidity, which mostly occurs in skin-restricted and systemic disorders, including localized scleroderma, systemic sclerosis (SSc) and chronic graft-versus-host disease. Fibrosis frequently develops as a result of epidermal or dermal damage brought on by repeated chemical exposure or trauma. It frequently goes hand in hand with chronic inflammation and is defined by an increase in fibrous connective tissues in the dermis or subcutis.

The global skin fibrosis treatment market is estimated to be valued at US$ 609.6 million in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030).

Figure 1. Global Skin Fibrosis Treatment Market Share (%), by Distribution Channel, 2022

Skin Fibrosis Treatment  | Coherent Market Insights

Growing prevalence of systemic sclerosis which account one of the main cause for skin fibrosis among the population is expected to drive the global skin fibrosis treatment market.

The increasing prevalence of systemic sclerosis is expected to drive the market growth over the forecast period. For instance, in February 2021, according to data published by the BioMed Central Ltd, part of Springer Nature, prevalence of systemic sclerosis in Italy found out to be 22.2 per 100,000, with the highest prevalence observed for the cases aged ≥ 65 years. In females, SSc was predominant (86.7% on the total) with an overall sex ratio Female/Male of 6.5. Nevertheless, males presented a more severe disease, with a lower survival and notable differences in respiratory complications and metabolic comorbidities. According to the Center for Disease Control and Prevention, prevalence of systemic sclerosis in Europe and North America in 2019 was found to be 13.5-44.3 and 7.2-33.9 per 100,000 individuals.

Figure 2.Global Skin Fibrosis Treatment Market Value (US$ Million), by Region, 2022

Skin Fibrosis Treatment  | Coherent Market Insights

Rise in research & development activities for the development of skin fibrosis drugs are expected to drive the market growth during the forecast period.

Increasing research and development activities by the key players in the market for the development of skin fibrosis drugs are expected to drive the market growth over the forecast period. For instance, on March 14, 2022, Chemomab Therapeutics, Ltd., a clinical-stage biotechnology company, was focused on development and discovery of ingenious therapeutics for fibrotic and inflammatory diseases with high unmet need. CM-101, was presented with patient sample data and preclinical data as a novel therapy for the treatment of systemic sclerosis.

CMI table icon

Skin Fibrosis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 609.6 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.9% 2030 Value Projection: US$ 1,038.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Corticosteroids, Antifibrotic Drugs, Immunotherapy Drugs, Other (Immunosuppressant)
  • By Route of Administration: Oral, Parenteral, Other (Topical)
  • By Application: Localized forms of scleroderma, Eosinophilic fasciitis, Scleromyxedema (papular mucinosis), Scleredema
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 
Companies covered:

Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, , Bristol-Myers Squibb Company

Growth Drivers:
  • Growing prevalence of systemic sclerosis which account one of the main cause for skin fibrosis  among the population
  • Rise in research & development activities for the development of skin fibrosis drugs 
Restraints & Challenges:
  • High cost of the skin fibrosis drugs

Global Skin Fibrosis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global skin fibrosis treatment market, owing to the decrease in research and development activities for the treatment of the skin fibrosis. For instance, in December 2020, according to the data published by the National Center for Biotechnology Information, the research and development activities for the development of vaccines for prevention of coronavirus was on priority. The clinicians and the medical physicians were engaged in the clinical trials and Food and Drug Administration approval for the vaccines used in immunization against COVID-19. The research and development activities for the development of skin fibrosis drugs was slowdown as the impact and response of the Covid-19. The government of different countries imposed lockdown which restricted the availability of the required biological molecules for development of the skin fibrosis treatment drugs.

Global Skin Fibrosis Treatment Market: Key Developments

In May 2022, Michigan Medicine, University of Michigan Hospital, carried out studies on epigenetic drugs, which has shown promising results in cancer treatment significantly in reducing scarring in the cells of patients with scleroderma. The studies revealed that drugs that inhibit Bromodomain-containing protein 4(BRD4) can be used to treat fibrosis in scleroderma. The tests carried out by the researchers for the BRD4 inhibitors on the skin fibroblasts of scleroderma patients and in mice models of skin fibrosis showed that treatment terminated scarring in both animals and in human-derived cells.

Global Skin Fibrosis Treatment Market: Restraint

The major factors that hinder growth of the global skin fibrosis treatment market include high cost of the skin fibrosis drugs. For instance, in April 2017, according to the data published by the Vertex Pharmaceuticals, Biotech Company, include Orkambi (ivacaftor/lumacaftor), Trikafta (ivacaftor/tezacaftor/elexacaftor), carry high list prices between US$ 270,000 and US$ 310,000 per year. The patients with skin fibrosis needs treatment for life time which becomes difficult for people with low income to continue with the skin fibrosis treatment therapy.

Key Players

Major players operating in the global skin fibrosis treatment market include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, Bristol-Myers Squibb Company

Skin fibrosis generally occurs in patients who suffer from eosinophilia-myalgia syndrome, scleromyxedema (papular mucinosis) and scleredema. Fibrosis frequently develops as a result of continuous chemical exposure or trauma that causes epidermal or dermal harm. It is characterized by an increase of fibrous connective tissues in the dermis or subcutis and frequently goes hand in hand with persistent inflammation. Fibrosis frequently develops as a result of epidermal or dermal damage brought on by repeated chemical exposure or trauma. An increase in fibrous connective tissues in the dermis is one of its defining features. Systemic sclerosis (SSc also known as scleroderma), which also causes fibrosis in a number of other organs, is characterized by the primary symptom of skin fibrosis. Although, this fibrosis cannot be reversed, it can be treated to some extent using currently available drugs. Dermal fibrosis, which results from a pathologic reaction to wound healing, is excessive skin scarring. Scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis are only a few of the many fibrotic skin illnesses that exist.

Market Dynamics

The rise in recent advances in treatment for the skin fibrosis is expected to drive the global skin fibrosis treatment market growth over the forecast period. For instance, in December 2017, according to the data published by the Springer Nature, the new treatment strategy has shown promising results in the treatment of skin fibrosis. The treatment involves the molecular targeting therapy with monoclonal antibody. The positive clinical outcomes had been reported in rituximab (an anti-CD20 antibody) and the tocilizumab (an anti-interleukin-6 (IL-6) receptor antibody).

Key features of the study:

  • This report provides an in-depth analysis of the global skin fibrosis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global skin fibrosis treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, , Bristol-Myers Squibb Company
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global skin fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin fibrosis treatment market

Detailed Segmentation:

  • Global Skin Fibrosis Treatment Market, By Drug Type:
    • Corticosteroids
    • Antifibrotic Drugs
    • Immunotherapy Drugs
    • Other (Immunosuppressant)
  • Global Skin Fibrosis Treatment Market, By Route of Administration:
    • Oral
    • Parenteral
    • Others ( Topical)
  • Global Skin Fibrosis Treatment Market, By Application:
    • Localized forms of scleroderma
    • Eosinophilic fasciitis
    • Scleromyxedema (papular mucinosis)
    • Scleredema
  • Global Skin Fibrosis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies 
  • Global Skin Fibrosis Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pharmaxis
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Jubilant Cadista
    • Horizon Pharma USA
    • Pfizer
    • Sanofi
    • Hoffmann-La Roche
    • Boehringer Ingelheim
    • Bristol-Myers Squibb Company

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global skin fibrosis treatment market size is estimated to be valued at US$ 609.6 million in 2022 and is expected to exhibit a CAGR of 6.9% between 2022 and 2030.
Factors such as growing prevalence of systemic sclerosis which account one of the main cause for skin fibrosis among the population and rise in research & development activities for the development of skin fibrosis drugs are expected to drive the market growth.
Hospital Pharmacies is the leading distribution channel segment in the market.
The major factors hampering growth of the market include high cost of the skin fibrosis drugs.
Major players operating in the market include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, , Bristol-Myers Squibb Company

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo